Novartis hemoglobinuria trial meets two primary endpoints
admin Novartis AG NOVN, +0.47% NVS, +2.05% said Monday that a study on a drug to…
Read MoreIndustrial Goods
Early chip earnings provided a sigh of relief, but two more big tests are coming
Early chip-industry earnings reporters have provided a sigh of relief in a sector where many…
Read MoreInaugural Honeywell survey reveals strong corporate efforts to cut energy waste
Companies are setting aside more budget for energy and environmental sustainability as investors, consumers and…
Read MorePollster Frank Luntz gives midterm election warning: ‘I don’t think we’re going to have a clear result’
“ ‘I’m warning the markets now that I don’t think we’re going to have a…
Read MoreLeaked draft of German government’s cannabis reform would ban imports — for now
A leaked document from German health minister Karl Lauterbach that lays out the regulatory framework…
Read MoreRexel probe, Schneider Electric and Legrand indicted after French pricing probe
Rexel SA said Friday that one of its business units has been placed under formal…
Read MoreIntel reportedly to start ‘targeted’ layoffs in November
Intel Corp. is planning on announcing “targeted” layoffs in November, according to a report late…
Read MoreShould you stake ether, when U.S. Treasuries are yielding more ?
Hello, welcome back to Distributed Ledger, our weekly crypto newsletter that reaches your inbox every…
Read MoreLam Research surges 10% after strong earnings — has stock finally hit a bottom?
Lam Research Corp. shares rallied Thursday as Wall Street cut their target prices, anticipating a…
Read More
Raymond James ‘tapping out’ of home-builder stocks as a housing recession is now a given
Raymond James analyst Buck Horne lowered ratings on all of the home-builder stocks he covers,…
Read More